S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

GRF Eagle Capital Growth Fund Inc

9.85

0.00 (0.00%)

Pre Market

Last Updated: 21:00:02

Delayed by 15 minutes

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)

Eagle Capital Growth (AMEX:GRF)
Historical Stock Chart
From Aug 2024 to Sep 2024

Click Here for more Eagle Capital Growth Charts.

Eagle Capital Growth (AMEX:GRF)
Historical Stock Chart
From Sep 2023 to Sep 2024

Click Here for more Eagle Capital Growth Charts.

Eagle Capital Growth Fund Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 11 September 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 11 September 2024 (2 weeks ago) • Edgar (US Regulatory)

Form N-PX - Annual Report of proxy voting record of management investment companies
Friday 30 August 2024 (4 weeks ago) • Edgar (US Regulatory)

GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339
Wednesday 31 July 2024 (2 months ago) • GlobeNewswire Inc.

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
Monday 29 July 2024 (2 months ago) • GlobeNewswire Inc.

Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
Monday 1 July 2024 (3 months ago) • GlobeNewswire Inc.

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
Tuesday 18 June 2024 (3 months ago) • GlobeNewswire Inc.

Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
Monday 17 June 2024 (3 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 25 May 2024 (4 months ago) • Edgar (US Regulatory)

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
Thursday 18 April 2024 (5 months ago) • GlobeNewswire Inc.

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
Thursday 4 April 2024 (6 months ago) • GlobeNewswire Inc.

Form DEF 14A - Other definitive proxy statements
Friday 8 March 2024 (7 months ago) • Edgar (US Regulatory)

More Eagle Capital Growth Fund Inc News Articles

NLBNPIT20912 20991231 11...

Pacer Nasdaq 100 Trendpi...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions